Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Livia Puljak, Małgorzata M Bala, Joanna Zając, Tomislav Meštrović, Sandra Buttiġieġ, Mary Yanakoulia, Matthias Briel, Carole Lunny, Wiktoria Lesniak, Tina Poklepović Peričić, Pablo Alonso-Coello, Mike Clarke, Benjamin Djulbegovic, Gerald Gartlehner, Konstantinos Giannakou, Anne-Marie Glenny, Claire Glenton, Gordon Guyatt, Lars G Hemkens, John P A Ioannidis, Roman Jaeschke, Karsten Juhl Jørgensen, Carolina Castro Martins-Pfeifer, Ana Marušić, Lawrence Mbuagbaw, Jose Francisco Meneses Echavez, David Moher, Barbara Nussbaumer-Streit, Matthew J Page, Giordano Pérez-Gaxiola, Karen A Robinson, Georgia Salanti, Ian J Saldanha, Jelena Savović, James Thomas, Andrea C Tricco, Peter Tugwell, Joost van Hoof, Dawid Pieper
OBJECTIVES: Evidence-based research (EBR) is the systematic and transparent use of prior research to inform a new study so that it answers questions that matter in a valid, efficient, and accessible manner. This study surveyed experts about existing (e.g. citation analysis) and new methods for monitoring EBR and collected ideas about implementing these methods. STUDY DESIGN AND SETTING: We conducted a cross-sectional study via an online survey between November 2022 and March 2023...
January 5, 2024: Journal of Clinical Epidemiology
#22
Christopher D Pfledderer, Lauren von Klinggraeff, Sarah Burkart, Alexsandra da Silva Bandeira, David R Lubans, Russ Jago, Anthony D Okely, Esther Mf van Sluijs, John Pa Ioannidis, James F Thrasher, Xiaoming Li, Michael W Beets
Background In the behavioral sciences, conducting pilot and/or feasibility studies (PFS) is a key step that provides essential information used to inform the design, conduct, and implementation of a larger-scale trial. There are more than 160 published guidelines, reporting checklists, frameworks, and recommendations related to PFS. All of these publications offer some form of guidance on PFS, but many focus on one or a few topics. This makes it difficult for researchers wanting to gain a broader understanding of all the relevant and important aspects of PFS and requires them to seek out multiple sources of information, which increases the risk of missing key considerations to incorporate into their PFS...
December 15, 2023: Research Square
#23
JOURNAL ARTICLE
Maximilian Siebert, John P A Ioannidis
No abstract text is available yet for this article.
December 28, 2023: JAMA
#24
JOURNAL ARTICLE
Marc Raynaud, Solaf Al-Awadhi, Kevin Louis, Huanxi Zhang, Xiaojun Su, Valentin Goutaudier, Jiali Wang, Zeynep Demir, Yongcheng Wei, Agathe Truchot, Antoine Bouquegneau, Arnaud Del Bello, Élodie Bailly, Yannis Lombardi, Mehdi Maanaoui, Alessia Giarraputo, Sofia Naser, Gillian Divard, Olivier Aubert, Mohammad Hassan Murad, Changxi Wang, Longshan Liu, Oriol Bestard, Maarten Naesens, John J Friedewald, Carmen Lefaucheur, Leonardo Riella, Gary Collins, John P A Ioannidis, Alexandre Loupy
SIGNIFICANCE STATEMENT: Why are there so few biomarkers accepted by health authorities and implemented in clinical practice, despite the high and growing number of biomaker studies in medical research ? In this meta-epidemiological study, including 804 studies that were critically appraised by expert reviewers, the authors have identified all prognostic kidney transplant biomarkers and showed overall suboptimal study designs, methods, results, interpretation, reproducible research standards, and transparency...
February 1, 2024: Journal of the American Society of Nephrology: JASN
#25
JOURNAL ARTICLE
John P A Ioannidis, Zacharias Maniadis
Qualitative assessments of researchers are resource-intensive, untenable in nonmeritocratic settings, and error-prone. Although often derided, quantitative metrics could help improve research practices if they are rigorous, field-adjusted, and centralized.
December 2023: PLoS Biology
#26
JOURNAL ARTICLE
Alena Chalupka, Lukas Richter, Ali Chakeri, Ziad El-Khatib, Verena Theiler-Schwetz, Christian Trummer, Robert Krause, Peter Willeit, Bernhard Benka, John P A Ioannidis, Stefan Pilz
INTRODUCTION: Evidence is limited on the effectiveness of a fourth vaccine dose against coronavirus disease 2019 (COVID-19) in populations with prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. We estimated the risk of COVID-19 deaths and SARS-CoV-2 infections according to vaccination status in previously infected individuals in Austria. METHODS: This is a nationwide retrospective observational study. We calculated age and gender adjusted Cox proportional hazard ratios (HRs) of COVID-19 deaths (primary outcome) and SARS-CoV-2 infections (secondary outcome) from 1 November to 31 December 2022, primarily comparing individuals with four versus three vaccine doses...
November 30, 2023: European Journal of Clinical Investigation
#27
JOURNAL ARTICLE
John P A Ioannidis, Francesco Zonta, Michael Levitt
Excess deaths provide total impact estimates of major crises, such as the COVID-19 pandemic. We evaluated excess death trajectories across countries with accurate death registration and population age structure data and assessed relationships with vulnerability indicators. Using the Human Mortality Database on 34 countries, excess deaths were calculated for 2020-2023 (to week 29, 2023) using 2017-2019 as reference, with adjustment for 5 age strata. Countries were divided into less and more vulnerable; the latter had per capita nominal GDP < $30,000, Gini > 0...
December 5, 2023: Proceedings of the National Academy of Sciences of the United States of America
#28
JOURNAL ARTICLE
Qian Feng, Ben W Mol, John P A Ioannidis, Wentao Li
STUDY QUESTION: What were the frequency and temporal trends of reporting P-values and effect measures in the abstracts of reproductive medicine studies in 1990-2022, how were reported P-values distributed, and what proportion of articles that present with statistical inference reported statistically significant results, i.e. 'positive' results? SUMMARY ANSWER: Around one in six abstracts reported P-values alone without effect measures, while the prevalence of effect measures, whether reported alone or accompanied by P-values, has been increasing, especially in meta-analyses and randomized controlled trials (RCTs); the reported P-values were frequently observed around certain cut-off values, notably at 0...
November 28, 2023: Human Reproduction
#29
JOURNAL ARTICLE
Suzanne N Morin, Sidney Feldman, Larry Funnell, Lora Giangregorio, Sandra Kim, Heather McDonald-Blumer, Nancy Santesso, Rowena Ridout, Wendy Ward, Maureen C Ashe, Zahra Bardai, Joan Bartley, Neil Binkley, Steven Burrell, Debra Butt, Suzanne M Cadarette, Angela M Cheung, Phil Chilibeck, Sheila Dunn, Jamie Falk, Heather Frame, William Gittings, Kaleen Hayes, Carol Holmes, George Ioannidis, Susan B Jaglal, Robert Josse, Aliya A Khan, Virginia McIntyre, Lynn Nash, Ahmed Negm, Alexandra Papaioannou, Matteo Ponzano, Isabel B Rodrigues, Lehana Thabane, Christine A Thomas, Lianne Tile, John D Wark
No abstract text is available yet for this article.
November 26, 2023: Canadian Medical Association Journal: CMAJ
#30
JOURNAL ARTICLE
John P A Ioannidis, Kevin W Boyack, Thomas A Collins, Jeroen Baas
We evaluated how the gender composition of top-cited authors within different subfields of research has evolved over time. We considered 9,071,122 authors with at least 5 full papers in Scopus as of September 1, 2022. Using a previously validated composite citation indicator, we identified the 2% top-cited authors for each of 174 science subfields (Science-Metrix classification) in 4 separate publication age cohorts (first publication pre-1992, 1992 to 2001, 2002 to 2011, and post-2011). Using NamSor, we assigned 3,784,507 authors as men and 2,011,616 as women (for 36...
November 2023: PLoS Biology
#31
RANDOMIZED CONTROLLED TRIAL
Leonardo M Siena, Lazaros Papamanolis, Maximilian J Siebert, Rosa Katia Bellomo, John P A Ioannidis
IMPORTANCE: Industry involvement is prominent in influential clinical trials, and commitments to transparency of trials are highly variable. OBJECTIVE: To evaluate the modes of industry involvement and the transparency features of the most cited recent clinical trials across medicine. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study was a meta-research assessment including randomized and nonrandomized clinical trials published in 2019 or later...
November 1, 2023: JAMA Network Open
#32
REVIEW
John P A Ioannidis, Zacharias Maniadis
Quantitative bibliometric indicators are widely used and widely misused for research assessments. Some metrics have acquired major importance in shaping and rewarding the careers of millions of scientists. Given their perceived prestige, they may be widely gamed in the current "publish or perish" or "get cited or perish" environment. This review examines several gaming practices, including authorship-based, citation-based, editorial-based, and journal-based gaming as well as gaming with outright fabrication...
November 3, 2023: Internal and Emergency Medicine
#33
JOURNAL ARTICLE
Dorthe B Berthelsen, Lee S Simon, John P A Ioannidis, Marieke Voshaar, Pam Richards, Niti Goel, Vibeke Strand, Sabrina M Nielsen, Beverly J Shea, Peter Tugwell, Susan J Bartlett, Glen S Hazlewood, Lyn March, Jasvinder A Singh, Maria E Suarez-Almazor, Maarten Boers, Randall M Stevens, Daniel E Furst, Thasia Woodworth, Amye Leong, Peter M Brooks, Caroline Flurey, Robin Christensen
OBJECTIVES: To develop an understanding of the concept of safety/harms experienced by patients involved in clinical trials for their rheumatic and musculoskeletal diseases (RMDs) and to seek input from the OMERACT community before moving forward to developing or selecting an outcome measurement instrument. METHODS: OMERACT 2023 presented and discussed interview results from 34 patients indicating that up to 171 items might be important for patients' harm-reporting...
October 26, 2023: Seminars in Arthritis and Rheumatism
#34
REVIEW
Soo Young Hwang, Dong Keon Yon, Seung Won Lee, Min Seo Kim, Jong Yeob Kim, Lee Smith, Ai Koyanagi, Marco Solmi, Andre F Carvalho, Eunyoung Kim, Jae Il Shin, John P A Ioannidis
BACKGROUND: Many studies have evaluated the prevalence of different reasons for retraction in samples of retraction notices. We aimed to perform a systematic review of such empirical studies of retraction causes. METHODS: The PubMed/MEDLINE database and the Embase database were searched in June 2023. Eligible studies were those containing sufficient data on the reasons for retraction across samples of examined retracted notices. RESULTS: A 11,181 potentially eligible items were identified, and 43 studies of retractions were included in this systematic review...
October 23, 2023: Journal of Korean Medical Science
#35
JOURNAL ARTICLE
Robert T Thibault, Marton Kovacs, Tom E Hardwicke, Alexandra Sarafoglou, John P A Ioannidis, Marcus R Munafò
Background. Although preregistration can reduce researcher bias and increase transparency in primary research settings, it is less applicable to secondary data analysis. An alternative method that affords additional protection from researcher bias, which cannot be gained from conventional forms of preregistration alone, is an Explore and Confirm Analysis Workflow (ECAW). In this workflow, a data management organization initially provides access to only a subset of their dataset to researchers who request it...
October 2023: Royal Society Open Science
#36
JOURNAL ARTICLE
Mashaal Sohail, María J Palma-Martínez, Amanda Y Chong, Consuelo D Quinto-Cortés, Carmina Barberena-Jonas, Santiago G Medina-Muñoz, Aaron Ragsdale, Guadalupe Delgado-Sánchez, Luis Pablo Cruz-Hervert, Leticia Ferreyra-Reyes, Elizabeth Ferreira-Guerrero, Norma Mongua-Rodríguez, Sergio Canizales-Quintero, Andrés Jimenez-Kaufmann, Hortensia Moreno-Macías, Carlos A Aguilar-Salinas, Kathryn Auckland, Adrián Cortés, Víctor Acuña-Alonzo, Christopher R Gignoux, Genevieve L Wojcik, Alexander G Ioannidis, Selene L Fernández-Valverde, Adrian V S Hill, María Teresa Tusié-Luna, Alexander J Mentzer, John Novembre, Lourdes García-García, Andrés Moreno-Estrada
Latin America continues to be severely underrepresented in genomics research, and fine-scale genetic histories and complex trait architectures remain hidden owing to insufficient data1 . To fill this gap, the Mexican Biobank project genotyped 6,057 individuals from 898 rural and urban localities across all 32 states in Mexico at a resolution of 1.8 million genome-wide markers with linked complex trait and disease information creating a valuable nationwide genotype-phenotype database. Here, using ancestry deconvolution and inference of identity-by-descent segments, we inferred ancestral population sizes across Mesoamerican regions over time, unravelling Indigenous, colonial and postcolonial demographic dynamics2-6 ...
October 11, 2023: Nature
#37
JOURNAL ARTICLE
Suzanne N Morin, Sidney Feldman, Larry Funnell, Lora Giangregorio, Sandra Kim, Heather McDonald-Blumer, Nancy Santesso, Rowena Ridout, Wendy Ward, Maureen C Ashe, Zahra Bardai, Joan Bartley, Neil Binkley, Steven Burrell, Debra Butt, Suzanne M Cadarette, Angela M Cheung, Phil Chilibeck, Sheila Dunn, Jamie Falk, Heather Frame, William Gittings, Kaleen Hayes, Carol Holmes, George Ioannidis, Susan B Jaglal, Robert Josse, Aliya A Khan, Virginia McIntyre, Lynn Nash, Ahmed Negm, Alexandra Papaioannou, Matteo Ponzano, Isabel B Rodrigues, Lehana Thabane, Christine A Thomas, Lianne Tile, John D Wark
BACKGROUND: In Canada, more than 2 million people live with osteoporosis, a disease that increases the risk for fractures, which result in excess mortality and morbidity, decreased quality of life and loss of autonomy. This guideline update is intended to assist Canadian health care professionals in the delivery of care to optimize skeletal health and prevent fractures in postmenopausal females and in males aged 50 years and older. METHODS: This guideline is an update of the 2010 Osteoporosis Canada clinical practice guideline on the diagnosis and management of osteoporosis in Canada...
October 10, 2023: Canadian Medical Association Journal: CMAJ
#38
JOURNAL ARTICLE
Arnaud Chiolero, Stefano Tancredi, John P A Ioannidis
Surveillance and research data, despite their massive production, often fail to inform evidence-based and rigorous data-driven health decision-making. In the age of infodemic, as revealed by the COVID-19 pandemic, providing useful information for decision-making requires more than getting more data. Data of dubious quality and reliability waste resources and create data-genic public health damages. We call therefore for a slow data public health, which means focusing, first, on the identification of specific information needs and, second, on the dissemination of information in a way that informs decision-making, rather than devoting massive resources to data collection and analysis...
October 3, 2023: European Journal of Epidemiology
#39
EDITORIAL
John P A Ioannidis, Michael Berkwits, Annette Flanagin, Theodora Bloom
No abstract text is available yet for this article.
September 22, 2023: BMJ: British Medical Journal
#40
JOURNAL ARTICLE
Seth C Inzaule, Mark J Siedner, Susan J Little, Santiago Avila-Rios, Alisen Ayitewala, Ronald J Bosch, Vincent Calvez, Francesca Ceccherini-Silberstein, Charlotte Charpentier, Diane Descamps, Susan H Eshleman, Joseph Fokam, Lisa M Frenkel, Ravindra K Gupta, John P A Ioannidis, Pontiano Kaleebu, Rami Kantor, Seble G Kassaye, Sergei L Kosakovsky Pond, Vinie Kouamou, Roger D Kouyos, Daniel R Kuritzkes, Richard Lessells, Anne-Genevieve Marcelin, Lawrence Mbuagbaw, Brian Minalga, Nicaise Ndembi, Richard A Neher, Roger Paredes, Deenan Pillay, Elliot G Raizes, Soo-Yon Rhee, Douglas D Richman, Kiat Ruxrungtham, Pardis C Sabeti, Jonathan M Schapiro, Sunee Sirivichayakul, Kim Steegen, Wataru Sugiura, Gert U van Zyl, Anne-Mieke Vandamme, Annemarie M J Wensing, Joel O Wertheim, Huldrych F Gunthard, Michael R Jordan, Robert W Shafer
Author summary • Human immunodeficiency virus (HIV) drug resistance has implications for antiretroviral treatment strategies and for containing the HIV pandemic because the development of HIV drug resistance leads to the requirement for antiretroviral drugs that may be less effective, less well-tolerated, and more expensive than those used in first-line regimens. • HIV drug resistance studies are designed to determine which HIV mutations are selected by antiretroviral drugs and, in turn, how these mutations affect antiretroviral drug susceptibility and response to future antiretroviral treatment regimens...
September 22, 2023: PLoS Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
